Proposals are welcome for the Breakfast Symposia, Junior Member Seminars, and Parallel Seminars.

 

Click here to View the 2020 Scientific Program Proposal Submission Guidelines and Apply!

Deadline : 1st November 2019

 

Take note of other important dates and deadlines here below :

 

ICNA will be having a stand during the EPNS meeting from the 17-21 September in Athens Greece ( Next to the EPNS stand Opposite Booth 61).   Pass by to collect our flyers for the ICNC2020 with important dates and information, or learn more about ICNA , and our Education and Research Committees.   Mc Keith Press will also be offering a 20% discount on the IRCN book series published together with ICNA at their EPNS Mac Keith Press stand (or online at www.mackeith.co.uk using coupon code EPNS20)    

   

Dear Members,

This is to inform you that Mac Keith Press have recently published the book Neuromuscular Disorders in Children: A Multidisciplinary Approach to Management edited by Nicolas Deconinck and Nathalie Goemans, which could be of great interest to you: 

http://www.mackeith.co.uk/shop/neuromuscular-disorders-in-children-a-multidisciplinary-approach-to-management/

The book critically reviews current evidence of management approaches in the field of neuromuscular disorders (NMDs) in children. Uniquely, the book focusses on assessment as the cornerstone of management and highlights the importance of a multidisciplinary approach.

From the Foreword

“Neuromuscular Disorders in Children… is consistently patient-centred, will help readers learn about the latest classification and treatment options for these diseases, and hopefully influence their attitudes and decisions caring for patients with NMDs. With broad distribution, this book will help to improve the fate and quality of life of many patients suffering from NMDs, as well as their families.”

Rudolf Korinthenberg MD, Professor Emeritus of Neuropaediatrics and Muscular Disorders

Emerging genetic therapies for rare disorders at high cost, cannot realistically address the global burden of disease - Stakeholders must develop new pathways to ensure safe, fair and sustainable provision of such therapies A disease or disorder is defined as rare in Europe when it affects fewer than 1 in 2000 people and based on the Food and drug administration (FDA) definition from the US, when it affects less than 200,000 at any one time. Genetic factors contribute to the etiology in 80% of those with rare diseases, and other contributing factors, including infection, account for the remaining the cases....